Castle Biosciences (CSTL)
(Delayed Data from NSDQ)
$14.65 USD
-0.50 (-3.30%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $14.63 -0.02 (-0.14%) 7:58 PM ET
4-Sell of 5 4
B Value D Growth C Momentum B VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
CSTL 14.65 -0.50(-3.30%)
Will CSTL be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for CSTL based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CSTL
New Strong Sell Stocks for August 1st
TG Therapeutics (TGTX) Earnings Expected to Grow: What to Know Ahead of Q2 Release
CSTL: What are Zacks experts saying now?
Zacks Private Portfolio Services
Earnings Preview: Castle Biosciences, Inc. (CSTL) Q2 Earnings Expected to Decline
Castle Biosciences, Inc. (CSTL) Reports Q1 Loss, Tops Revenue Estimates
GSK (GSK) Q1 Earnings Surpass Estimates
Other News for CSTL
Examining the Future: Castle Biosciences's Earnings Outlook
Castle Biosciences to Present at the Canaccord Genuity 45th Annual Growth Conference | CSTL ...
Castle Biosciences' Founder, President and CEO Derek Maetzold Named a Most Admired CEO by the ...
Castle Biosciences, Revolution Medicines get FDA breakthrough statuses
Castle Biosciences (CSTL) Gains FDA Breakthrough Device Status for Melanoma Test | CSTL Stock News